CG Oncology, Inc. business relationships
Companies named in CG Oncology, Inc.’s 10-K filed 2026-02-27, and public companies whose annual reports name CG Oncology, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 6 / 100 Top 5% in its category
- Agent readiness
- 20 / 100
- AI adoption
- 0 / 100
Named in CG Oncology, Inc.’s annual report 3
“In January 2020, pembrolizumab, sold by Merck, was approved by the FDA to treat high-risk BCG-unresponsive NMIBC as monotherapy based on the results of the KEYNOTE-057 Phase 2 clinical trial.” SEC filing
“While there are other options globally for BCG, none of the options are available in the United States, except for the TICE BCG strain manufactured by Merck.” SEC filing
“...d conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Biovire, Inc., which is included in the 2025 consolidated financial statements of the Company and constituted 5% of total as of December 31, 2025, and 80% and 4% of revenues and ne...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.